SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-23-061021
Filing Date
2023-07-31
Accepted
2023-07-31 08:05:23
Documents
3
Period of Report
2023-07-31

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea182452-6k_enlivextherap.htm 6-K 9327
2 PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON JULY 31, 2023. ea182452ex99-1_enlivextherap.htm EX-99.1 10376
3 GRAPHIC image_001.jpg GRAPHIC 3875
  Complete submission text file 0001213900-23-061021.txt   26421
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 231125088
SIC: 2834 Pharmaceutical Preparations